ATG-102 / Antengene - LARVOL DELTA

ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML (AACR 2024) - "ATG-102 demonstrates trivalent, dual epitope recognition of LILRB4, conditionally redirects and activates T cells to recognize and kill monocytic AML cells. It demonstrates potent in vitro and in vivo anti-tumor efficacy with low risk of CRS."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CD69 • IL2RA • IL6 • LILRB4

Antengene Presents Four Preclinical Posters at AACR 2024 (PRNewswire) - "The poster outlines the design and structural characteristics of ATG-102 comprised of two LILRB4 epitopes and an anti-CD3 single chain fragment variable (scFv) inserted in the hinge region on one of the LILRB4 heavy chains. Characterization data include: (i) Binding epitope and affinity studies showing that ATG-102 binds to the target TAA epitopes as well as conformational CD3 epitopes; (ii) T cell binding and T-cell dependent cytotoxicity assays show that compared to the benchmark, ATG-102 demonstrated less non-specific T cell binding or activation, whilst inducing more potent TDCC against LILRB4+cells and enhanced in vivo anti-AML efficacy."

Preclinical • Acute Myelogenous Leukemia

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms (PRNewswire) - "Antengene Corporation Limited...announced that four preclinical abstracts have been selected as poster presentations at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024)....'At the meeting, we will present the first data from our MTAPnull-selective PRMT5 inhibitor program and the first candidate from our companion diagnostic program, a CDx to support our novel Claudin 18.2 ADC, ATG-022. In addition, we are keenly interested in T cell engagers and look forward to presenting results on Antengene's unique AnTenGager platform and one of our first lead programs targeting LILRB4 for Acute Myelogenous Leukemia (AML)'."

Diagnostic • Preclinical • Acute Myelogenous Leukemia • Solid Tumor